SCHEMBL7145600

SCHEMBL7145600

CCOC(=O)c1cnc(N)nc1-c1ccco1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 14/20 0.60
ADORA2A P29274 14/20 0.60
ADORA1 P30542 13/20 0.60
ADORA2B P29275 6/20 0.60
HSP90AA1 P07900 1/20 0.53
KDM4E B2RXH2 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
ALDH1A1 P00352 2/20 0.51
MEN1 O00255 1/20 0.51
ALOX15 P16050 1/20 0.51
KMT2A Q03164 1/20 0.51
HSD17B10 Q99714 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
MAPK1 P28482 1/20 0.48
ATM Q13315 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22573640 0.81 ADORA3 (0.66) ADORA3ADORA2AADORA1ADORA2BALDH1A1
SCHEMBL8722135 0.76 ADORA3 (0.48) ADORA3ADORA2AADORA1ADORA2BL3MBTL1
SCHEMBL1143375 0.75 HSP90AA1 (0.70) HSP90AA1KDM4EL3MBTL1ALDH1A1MEN1
SCHEMBL29623178 0.75 ADORA2B (0.57) ADORA3ADORA2AADORA1ADORA2BHSP90AA1
SCHEMBL7147842 0.75 ADORA2B (0.57) ADORA3ADORA2AADORA1ADORA2BHSP90AA1
SCHEMBL6623973 0.75 ADORA3 (1.00) ADORA3ADORA2AADORA1ADORA2B
SCHEMBL23162642 0.74 ADORA2B (0.59) ADORA3ADORA2AADORA1ADORA2BHSP90AA1
SCHEMBL29623266 0.74 ADORA2B (0.59) ADORA3ADORA2AADORA1ADORA2BHSP90AA1
SCHEMBL5093408 0.74 ADORA3 (0.47) ADORA3ADORA2AADORA1ADORA2BKDM4E
SCHEMBL7147816 0.74 ADORA2A (0.52) ADORA3ADORA2AADORA1ADORA2BKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA3 6/4885ADORA2A 1/4885ADORA1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.